Arrowhead Pharmaceuticals Inc. (ARWR) Misses Q3 EPS by 40c
Tweet
Share
E-mailGet Alerts ARWR Hot Sheet
Price: $85.59 -1.9%
Financial Fact:
OPERATING LOSS: -19.34M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Financial Fact:
OPERATING LOSS: -19.34M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Join SI Premium – FREE
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported Q3 EPS of ($1.26), $0.40 worse than the analyst estimate of ($0.86). Revenue for the quarter came in at $27.77 million versus the consensus estimate of $53.9 million.
For earnings history and earnings-related data on Arrowhead Pharmaceuticals Inc. (ARWR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
- Macquarie Upgrades DiDi Global (DIDIY) to Outperform
- Dare Bioscience (DARE) Tops Q2 EPS by 11c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
